Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’
Author:
Affiliation:
1. Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy
Abstract
Publisher
Oxford University Press (OUP)
Subject
Dermatology
Link
https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad082/49590939/llad082.pdf
Reference14 articles.
1. Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab;López Sanz;Clin Exp Dermatol,2023
2. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience;Martora;Clin Cosmet Investig Dermatol,2023
3. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa?;Martora;Skin Appendage Disord,2022
4. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review;Ruggiero;Biomedicines,2022
5. Paradoxical reaction in a patient with hidradenitis suppurativa undergoing adalimumab treatment;Ikeya;Acta Derm Venereol,2021
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-01
2. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data;Clinical, Cosmetic and Investigational Dermatology;2023-09
3. Adalimumab/betamethasone-dipropionate/calcipotriol;Reactions Weekly;2023-07-15
4. Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies;Dermatology and Therapy;2023-07-04
5. Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’;Clinical and Experimental Dermatology;2023-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3